515 related articles for article (PubMed ID: 27315084)
1. Statins and Their Effect on PCSK9-Impact and Clinical Relevance.
Taylor BA; Thompson PD
Curr Atheroscler Rep; 2016 Aug; 18(8):46. PubMed ID: 27315084
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
3. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
4. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
[TBL] [Abstract][Full Text] [Related]
5. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function.
Amput P; McSweeney C; Palee S; Phrommintikul A; Chattipakorn SC; Chattipakorn N
Biomed Pharmacother; 2019 Jan; 109():1171-1180. PubMed ID: 30551367
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.
Athyros VG; Tziomalos K; Doumas M; Sfikas G; Karagiannis A
Curr Pharm Des; 2017; 23(10):1477-1483. PubMed ID: 28128061
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Gebauer K; Reinecke H
Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
9. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
10. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
[TBL] [Abstract][Full Text] [Related]
11. Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors.
Eisen A; Giugliano RP
Curr Opin Cardiol; 2016 Nov; 31(6):644-653. PubMed ID: 27661220
[TBL] [Abstract][Full Text] [Related]
12. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease.
Alkhalil M
Curr Drug Metab; 2019; 20(1):72-82. PubMed ID: 30112987
[TBL] [Abstract][Full Text] [Related]
13. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment.
Sliz E; Kettunen J; Holmes MV; Williams CO; Boachie C; Wang Q; Männikkö M; Sebert S; Walters R; Lin K; Millwood IY; Clarke R; Li L; Rankin N; Welsh P; Delles C; Jukema JW; Trompet S; Ford I; Perola M; Salomaa V; Järvelin MR; Chen Z; Lawlor DA; Ala-Korpela M; Danesh J; Davey Smith G; Sattar N; Butterworth A; Würtz P
Circulation; 2018 Nov; 138(22):2499-2512. PubMed ID: 30524137
[TBL] [Abstract][Full Text] [Related]
14. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
15. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
[TBL] [Abstract][Full Text] [Related]
16. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
17. Role of PCSK9 in lipid metabolism and atherosclerosis.
Lin XL; Xiao LL; Tang ZH; Jiang ZS; Liu MH
Biomed Pharmacother; 2018 Aug; 104():36-44. PubMed ID: 29758414
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
Peng W; Qiang F; Peng W; Qian Z; Ke Z; Yi L; Jian Z; Chongrong Q
Int J Cardiol; 2016 Nov; 222():119-129. PubMed ID: 27494723
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 Inhibitors: Treating the Right Patients in Daily Practice.
King P; Nicholls SJ
Curr Cardiol Rep; 2017 Aug; 19(8):66. PubMed ID: 28643240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]